Companies Dominating the Rheumatic Myocarditis Treatment Landscape
- Siemens Healthcare GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CryoLife Inc.
- Edwards Lifesciences Corporation
- Neovasc Inc.
- HighLife SAS
- Abbott Laboratories
- Sanofi-aventis Groupe
- Pfizer Inc.
- Boston Scientific Corporation
- Medtronic PLC
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of rheumatic myocarditis treatment is assessed at USD 1.19 billion.
The rheumatic myocarditis treatment market size was over USD 1.1 billion in 2024 and is projected to reach USD 2.05 billion by 2037, growing at around 4.9% CAGR during the forecast period i.e., between 2025-2037. Rising prevalence of rheumatic fever and the growing availability of over-the-counter drugs will boost the market growth.
North America industry is likely to account for largest revenue share of 35% by 2037, propelled by increasing frequency of rheumatic fever and subsequently rheumatic myocarditis amongst several people, driven by rising awareness about the disease among people and high healthcare expenditure for treatment procedures.
The major players in the market are Siemens Healthcare GmbH, CryoLife Inc., Edwards Lifesciences Corporation, Neovasc Inc., HighLife SAS, Abbott Laboratories, Sanofi-aventis Groupe, Pfizer Inc., Boston Scientific Corporation, Medtronic PLC
